• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝脏树突状细胞在代谢性脂肪性肝炎的发生和发展中的作用。

Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis.

机构信息

Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico.

出版信息

Front Immunol. 2021 Mar 23;12:641240. doi: 10.3389/fimmu.2021.641240. eCollection 2021.

DOI:10.3389/fimmu.2021.641240
PMID:33833761
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8021782/
Abstract

Metabolic Associated Fatty liver disease (MAFLD) is a global health problem and represents the most common cause of chronic liver disease in the world. MAFLD spectrum goes from simple steatosis to cirrhosis, in between metabolic steatohepatitis with progressive fibrosis, which pathogenesis is not completely understood. Hence, the role of the immune system has become an important fact in the trigger of inflammatory cascades in metabolic steatohepatitis and in the activation of hepatic stellate cells (HSCs). Among, the more studied immune cells in the pathogenesis of MAFLD are macrophages, T cells, natural killer and dendritic cells. In particular, hepatic dendritic cells had recently attracted a special attention, with a dual role in the pathogenesis of MAFLD. These cells have the capacity to switch from a tolerant state to active state inducing an inflammatory cascade. Furthermore, these cells play a role in the lipid storage within the liver, having, thus providing a crucial nexus between inflammation and lipid metabolism. In this review, we will discuss the current knowledge on the dual role of dendritic cells in lipid accumulation, as wells as in the triggering of hepatic inflammation and hepatocytes cell death in metabolic steatohepatitis.

摘要

代谢相关性脂肪性肝病(MAFLD)是一个全球性的健康问题,也是世界范围内最常见的慢性肝病病因。MAFLD 谱从单纯性脂肪变性到肝硬化,其间为伴有进行性纤维化的代谢性脂肪性肝炎,其发病机制尚不完全清楚。因此,免疫系统的作用在代谢性脂肪性肝炎的炎症级联反应触发和肝星状细胞(HSCs)的激活中已成为一个重要因素。在 MAFLD 的发病机制中,研究较多的免疫细胞包括巨噬细胞、T 细胞、自然杀伤细胞和树突状细胞。特别是,肝树突状细胞最近引起了特别关注,在 MAFLD 的发病机制中具有双重作用。这些细胞具有从耐受状态向激活状态转变的能力,从而诱导炎症级联反应。此外,这些细胞在肝脏内的脂质储存中发挥作用,从而在炎症和脂质代谢之间提供了一个关键的连接点。在这篇综述中,我们将讨论目前关于树突状细胞在脂质积累以及在代谢性脂肪性肝炎中触发肝炎症和肝细胞死亡中的双重作用的知识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f2/8021782/775933fc0f56/fimmu-12-641240-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f2/8021782/3fa906e265be/fimmu-12-641240-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f2/8021782/775933fc0f56/fimmu-12-641240-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f2/8021782/3fa906e265be/fimmu-12-641240-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18f2/8021782/775933fc0f56/fimmu-12-641240-g0002.jpg

相似文献

1
Hepatic Dendritic Cells in the Development and Progression of Metabolic Steatohepatitis.肝脏树突状细胞在代谢性脂肪性肝炎的发生和发展中的作用。
Front Immunol. 2021 Mar 23;12:641240. doi: 10.3389/fimmu.2021.641240. eCollection 2021.
2
Liver inflammation and fibrosis.肝脏炎症和纤维化。
J Clin Invest. 2017 Jan 3;127(1):55-64. doi: 10.1172/JCI88881.
3
Cutting Edge: Hepatic Stellate Cells Drive the Phenotype of Monocyte-derived Macrophages to Regulate Liver Fibrosis in Metabolic Dysfunction-associated Steatohepatitis.前沿:肝星状细胞驱动单核细胞来源的巨噬细胞表型调控代谢相关脂肪性肝炎中的肝纤维化。
J Immunol. 2024 Aug 1;213(3):251-256. doi: 10.4049/jimmunol.2300847.
4
Macrophages in metabolic associated fatty liver disease.代谢相关性脂肪性肝病中的巨噬细胞。
World J Gastroenterol. 2020 Apr 28;26(16):1861-1878. doi: 10.3748/wjg.v26.i16.1861.
5
Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.半乳糖凝集素-3 与代谢相关脂肪性肝病肝纤维化严重程度的关系。
Protein Pept Lett. 2024;31(4):290-304. doi: 10.2174/0109298665301698240404061300.
6
Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis.肝星状细胞与肝纤维化中周围细胞的串扰。
Int Immunopharmacol. 2021 Oct;99:108051. doi: 10.1016/j.intimp.2021.108051. Epub 2021 Aug 18.
7
Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.代谢性炎症在非酒精性脂肪性肝病中作为肝纤维化的启动因素。
World J Gastroenterol. 2020 May 7;26(17):1993-2011. doi: 10.3748/wjg.v26.i17.1993.
8
Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.中性粒细胞:代谢相关脂肪性肝病发生发展中的一个新角色。
Int Immunopharmacol. 2021 Aug;97:107609. doi: 10.1016/j.intimp.2021.107609. Epub 2021 Apr 19.
9
The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation.KLB rs17618244 基因变异通过促进肝星状细胞活化与纤维性 MAFLD 相关。
EBioMedicine. 2021 Mar;65:103249. doi: 10.1016/j.ebiom.2021.103249. Epub 2021 Feb 25.
10
Murine CD103 dendritic cells protect against steatosis progression towards steatohepatitis.小鼠 CD103 树突状细胞可防止脂肪变性向脂肪性肝炎进展。
J Hepatol. 2017 Jun;66(6):1241-1250. doi: 10.1016/j.jhep.2017.01.008. Epub 2017 Jan 18.

引用本文的文献

1
Myeloid cells in chronic liver inflammation.慢性肝脏炎症中的髓样细胞。
Cell Mol Immunol. 2025 Jul 28. doi: 10.1038/s41423-025-01324-4.
2
Liver macrophages: development, dynamics, and functions.肝巨噬细胞:发育、动态变化及功能
Cell Mol Immunol. 2025 Jun 3. doi: 10.1038/s41423-025-01298-3.
3
Knowledge landscape of macrophage research in liver fibrosis: a bibliometric review of the literature from WoSCC.肝纤维化中巨噬细胞研究的知识图谱:基于科学引文索引扩展版(WoSCC)文献的文献计量学综述

本文引用的文献

1
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.拉丁美洲肝脏研究学会(ALEH)关于重新定义脂肪肝疾病的立场声明。
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):65-72. doi: 10.1016/S2468-1253(20)30340-X. Epub 2020 Nov 9.
2
Redefining fatty liver disease: an international patient perspective.重新定义脂肪肝疾病:国际患者视角。
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):73-79. doi: 10.1016/S2468-1253(20)30294-6. Epub 2020 Oct 5.
3
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
Front Pharmacol. 2025 May 8;16:1571879. doi: 10.3389/fphar.2025.1571879. eCollection 2025.
4
Immune cells in metabolic associated fatty liver disease: Global trends and hotspots (2004-2024).代谢相关脂肪性肝病中的免疫细胞:全球趋势与热点(2004 - 2024年)
World J Hepatol. 2025 Mar 27;17(3):103327. doi: 10.4254/wjh.v17.i3.103327.
5
Liver sinusoidal endothelial cells regulate the balance between hepatic immunosuppression and immunosurveillance.肝窦内皮细胞调节肝脏免疫抑制和免疫监视之间的平衡。
Front Immunol. 2025 Jan 17;15:1497788. doi: 10.3389/fimmu.2024.1497788. eCollection 2024.
6
The immunological interface: dendritic cells as key regulators in metabolic dysfunction-associated steatotic liver disease.免疫界面:树突状细胞作为代谢功能障碍相关脂肪性肝病的关键调节因子
FEBS Lett. 2025 Jul;599(14):1971-1981. doi: 10.1002/1873-3468.15072. Epub 2024 Dec 12.
7
Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice.中药方剂治疗代谢功能障碍相关脂肪性肝病:当前证据与实践
Front Med (Lausanne). 2024 Oct 8;11:1476419. doi: 10.3389/fmed.2024.1476419. eCollection 2024.
8
Uncovering the mechanism of troglitazone-mediated idiosyncratic drug-induced liver injury with individual-centric models.揭示曲格列酮介导的药物性肝损伤的个体中心模型机制。
Arch Toxicol. 2024 Nov;98(11):3875-3884. doi: 10.1007/s00204-024-03833-z. Epub 2024 Aug 6.
9
Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact.肠道微生物群和免疫细胞在代谢相关脂肪性肝病中的作用:临床影响。
Hepatol Int. 2024 Oct;18(Suppl 2):861-872. doi: 10.1007/s12072-024-10674-6. Epub 2024 Jul 12.
10
Insights into the Management of Chronic Hepatitis in Children-From Oxidative Stress to Antioxidant Therapy.儿童慢性肝炎的管理策略——从氧化应激到抗氧化治疗。
Int J Mol Sci. 2024 Mar 31;25(7):3908. doi: 10.3390/ijms25073908.
亚太肝病学会代谢相关性脂肪性肝病临床诊疗指南。
Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2. Epub 2020 Oct 1.
4
Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis.血脂异常是非酒精性脂肪性肝炎患者肝纤维化进展的一个危险因素。
F1000Res. 2020 Jan 28;9:56. doi: 10.12688/f1000research.21918.1. eCollection 2020.
5
Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health.非肥胖个体中的非酒精性脂肪性肝病:代谢健康的影响
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):713-715. doi: 10.1016/S2468-1253(20)30090-X. Epub 2020 May 12.
6
Looking into a new era for the approach of metabolic (dysfunction) associated fatty liver disease.展望代谢(功能障碍)相关脂肪性肝病治疗的新时代。
Ann Hepatol. 2020 May-Jun;19(3):227-229. doi: 10.1016/j.aohep.2020.04.001.
7
The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis.非酒精性脂肪性肝炎中肝纤维化的细胞途径。
Ann Transl Med. 2020 Mar;8(6):400. doi: 10.21037/atm.2020.02.184.
8
What's in a name? Renaming 'NAFLD' to 'MAFLD'.名字里有什么?将“非酒精性脂肪性肝病”重新命名为“代谢功能障碍相关脂肪性肝病” 。 (备注:MAFLD全称为Metabolic Dysfunction-Associated Fatty Liver Disease ,直译为代谢功能障碍相关脂肪性肝病 ,是对NAFLD(Non-alcoholic Fatty Liver Disease,非酒精性脂肪性肝病)的重新命名 。这里如果仅按字面意思翻译,可能不太能理解其背景含义,补充了备注供你参考。)
Liver Int. 2020 Jun;40(6):1254-1261. doi: 10.1111/liv.14478. Epub 2020 Apr 28.
9
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义:国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
10
Caveats for the implementation of global strategies against non-alcoholic fatty liver disease.非酒精性脂肪性肝病全球防治策略实施的注意事项。
J Hepatol. 2020 Jul;73(1):220. doi: 10.1016/j.jhep.2020.02.013. Epub 2020 Mar 27.